Premium
Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C
Author(s) -
Orito Etsuro,
Mizokami Masashi,
Suzuki Kaoru,
Ohba KenIchi,
Ohno Tomoyoshi,
Mori Masamiki,
Hayashi Katsuo,
Kato Koji,
Iino Shiro,
Lau Johnson Y. N.
Publication year - 1995
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890460205
Subject(s) - medicine , interferon , gastroenterology , hepatitis c virus , chronic hepatitis , immunology , alpha interferon , flaviviridae , hepatitis c , interferon alfa , virus , virology
To determine the virological factors associated with a favorable long‐term response to interferon‐α (IFN) therapy in chronic hepatitis C virus (HCV) infection, 61 Japanese patients with chronic HCV infection were treated with IFN for 24 weeks (780 million units in total) and followed for 8 to 16 months after cessation of therapy. Ten patients dropped out because of severe side effects. Of the 51 patients who completed IFN therapy, 23 showed complete and sustained response (CR→SR), 13 complete response with early relapse (CR→Rel), and 15 no response to IFN (NR). For the pretreatment serum HCV RNA level, 20/23 who had CR→SR had